Journal
CANCER JOURNAL
Volume 13, Issue 1, Pages 70-74Publisher
JONES AND BARTLETT PUBLISHERS
DOI: 10.1097/PPO.0b013e31803c6e3b
Keywords
genomic imprinting; LOI; colorectal cancer
Categories
Funding
- NCI NIH HHS [R37 CA054358-17, CA65145, R01 CA054358, R37 CA054358] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA065145, R37CA054358, R01CA054358] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The practice of clinical oncology historically has been rooted in therapy for established cancers, and over the past decade, early detection of the malignancy has occurred increasingly, allowing an increasing chance of cure by surgical intervention. Cancer prevention has been targeted largely to generic reduction of exposure to environmental carcinogens, such as smoking reduction. However, targeted identification of patients at increased risk and therapeutic tailored intervention in those patients have not taken hold in oncology, despite the enormous success of that approach in preventive cardiology. A paradigm of such a strategy for oncology may be the identification of patients with epigenetic alterations in progenitor cells and intervention before the development of the earliest identifiable neoplasms. We review studies of loss of imprinting of insulin-like growth factor 2 in colorectal cancer as an example of such a target for preventive oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available